Publications by authors named "Stefan Engst"

Claim this Profile
S
Supraphysiological levels of GDF11 induce striated muscle atrophy.
David W Hammers, Melissa Merscham-Banda, Jennifer Ying Hsiao, Stefan Engst, James J Hartman

EMBO Mol Med· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Frauke Bentzien, Marcus Zuzow, Nathan Heald, Anna Gibson, Yongchang Shi, Stefan Engst

Thyroid· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Timothy Forsyth, Patrick C Kearney, Byung Gyu Kim, Henry W B Johnson, Naing Aay, Stefan Engst

Bioorg Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.
Moon H Kim, Amy Lew Tsuhako, Erick W Co, Dana T Aftab, Frauke Bentzien, Stefan Engst

Bioorg Med Chem Lett· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design, synthesis, and biological evaluation of PIM kinase inhibitors.
Amy Lew Tsuhako, David S Brown, Elena S Koltun, Naing Aay, Arlyn Arcalas, Stefan Engst

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of XL413, a potent and selective CDC7 inhibitor.
Elena S Koltun, Amy Lew Tsuhako, David S Brown, Naing Aay, Arlyn Arcalas, Stefan Engst

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).
Kenneth D Rice, Naing Aay, Neel K Anand, Charles M Blazey, Owen J Bowles, Stefan Engst

ACS Med Chem Lett· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.
Kenneth D Rice, Moon H Kim, Joerg Bussenius, Neel K Anand, Charles M Blazey, Stefan Engst

Bioorg Med Chem Lett· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
Joerg Bussenius, Neel K Anand, Charles M Blazey, Owen J Bowles, Lynne Canne Bannen, Stefan Engst

Bioorg Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Klaus P Hoeflich, Mark Merchant, Christine Orr, Jocelyn Chan, Doug Den Otter, Stefan Engst

Cancer Res· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
F Michael Yakes, Jason Chen, Jenny Tan, Kyoko Yamaguchi, Yongchang Shi, Stefan Engst

Mol Cancer Ther· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Fawn Qian, Stefan Engst, Kyoko Yamaguchi, Peiwen Yu, Kwang-Ai Won

Cancer Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis